Randomized phase II study of preoperative letrozole (Femara) in combination with avastin [bavacizumab] in hormone receptor positive breast cancer.

Trial Profile

Randomized phase II study of preoperative letrozole (Femara) in combination with avastin [bavacizumab] in hormone receptor positive breast cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Letrozole (Primary)
  • Indications Advanced breast cancer; Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jun 2009 Novartis and Genentech added as trial sponsor as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Planned end date changed from 1 Dec 2009 to 1 May 2010 as reported by ClinicalTrials.gov.
    • 08 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top